Sections
History and Discovery | Structure–Activity Relations | Pharmacological Profile | Pharmacokinetics and Disposition | Mechanism of Action | Indications and Efficacy | Side Effects and Toxicology | Drug–Drug Interactions
Excerpt
Trazodone's sedative properties and association with orthostatic
hypotension eventually inspired an effort to discover a modified
molecule, utilizing receptor-binding techniques, which would possess
a more desirable pharmacological profile. This led to the development
of nefazodone (Taylor et al. 1986), which became available
for clinical use in the United States in 1994. Nefazodone can be
considered a member of the trazodone family because they share a
common active metabolite.